-
1
-
-
0016799492
-
Clinical patterns in Crohn's disease: a statistical study of 615 cases
-
Farmer RG, Hawk WA, Turnbull RB Jr, (1975) Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 68: 627-635.
-
(1975)
Gastroenterology
, vol.68
, pp. 627-635
-
-
Farmer, R.G.1
Hawk, W.A.2
Turnbull Jr., R.B.3
-
2
-
-
32144454172
-
The many roles of chemokines and chemokine receptors in inflammation
-
Charo IF, Ransohoff RM, (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-21.
-
(2006)
N Engl J Med
, vol.354
, pp. 610-621
-
-
Charo, I.F.1
Ransohoff, R.M.2
-
3
-
-
0033231492
-
Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis
-
Zabel BA, Agace WW, Campbell JJ, Heath HM, Parent D, et al. (1999) Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 190: 1241-1256.
-
(1999)
J Exp Med
, vol.190
, pp. 1241-1256
-
-
Zabel, B.A.1
Agace, W.W.2
Campbell, J.J.3
Heath, H.M.4
Parent, D.5
-
4
-
-
0344483879
-
Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK
-
Zaballos A, Gutierrez J, Varona R, Ardavin C, Márquez G, (1999) Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 162: 5671.
-
(1999)
J Immunol
, vol.162
, pp. 5671
-
-
Zaballos, A.1
Gutierrez, J.2
Varona, R.3
Ardavin, C.4
Márquez, G.5
-
5
-
-
0036910773
-
Involvement of CCL25 (TECK) in the generation of the murine small-intestineal CD8αα+CD3+ intraepithelial lymphocyte compartment
-
Marsal J, Svensson M, Ericsson A, Iranpour AH, Carramolino L, et al. (2002) Involvement of CCL25 (TECK) in the generation of the murine small-intestineal CD8αα+CD3+ intraepithelial lymphocyte compartment. Eur J Immunol 32: 3488-3497.
-
(2002)
Eur J Immunol
, vol.32
, pp. 3488-3497
-
-
Marsal, J.1
Svensson, M.2
Ericsson, A.3
Iranpour, A.H.4
Carramolino, L.5
-
6
-
-
0036802422
-
CCL25 mediates the localization of recently activated CD8αβ+ lymphocytes to the small-intestinal mucosa
-
Svensson M, Marsal J, Ericsson A, Carramolino L, Brodén T, et al. (2002) CCL25 mediates the localization of recently activated CD8αβ+ lymphocytes to the small-intestinal mucosa. J Clin Invest 110: 1113-1121.
-
(2002)
J Clin Invest
, vol.110
, pp. 1113-1121
-
-
Svensson, M.1
Marsal, J.2
Ericsson, A.3
Carramolino, L.4
Brodén, T.5
-
7
-
-
1342300522
-
Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine
-
Pabst O, Ohl L, Wendland M, Wurbel MA, Kremmer E, et al. (2004) Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine. J Exp Med 199: 411-416.
-
(2004)
J Exp Med
, vol.199
, pp. 411-416
-
-
Pabst, O.1
Ohl, L.2
Wendland, M.3
Wurbel, M.A.4
Kremmer, E.5
-
8
-
-
34547525608
-
CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine
-
Wendland M, Czeloth N, Mach N, Malissen B, Kremmer E, et al. (2007) CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc Natl Acad Sci USA 104: 6347-6352.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 6347-6352
-
-
Wendland, M.1
Czeloth, N.2
Mach, N.3
Malissen, B.4
Kremmer, E.5
-
9
-
-
77957244016
-
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
-
Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, et al. (2010) Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 335: 65-69.
-
(2010)
J Pharmacol Exp Ther
, vol.335
, pp. 65-69
-
-
Walters, M.J.1
Wang, Y.2
Lai, N.3
Baumgart, T.4
Zhao, B.N.5
-
10
-
-
0017227303
-
Development of a Crohn's disease activity index
-
Best WR, Becktel JM, Singleton JW, Kern F, (1976) Development of a Crohn's disease activity index. Gastroenterology 70: 439-444.
-
(1976)
Gastroenterology
, vol.70
, pp. 439-444
-
-
Best, W.R.1
Becktel, J.M.2
Singleton, J.W.3
Kern, F.4
-
11
-
-
0024356033
-
Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicenter study
-
Mary JY, Modigliani R, (1989) Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicenter study. Gut 30: 983-989.
-
(1989)
Gut
, vol.30
, pp. 983-989
-
-
Mary, J.Y.1
Modigliani, R.2
-
12
-
-
0036161216
-
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
-
Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, et al. (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122: 512-530.
-
(2002)
Gastroenterology
, vol.122
, pp. 512-530
-
-
Sandborn, W.J.1
Feagan, B.G.2
Hanauer, S.B.3
Lochs, H.4
Lofberg, R.5
-
13
-
-
0034327830
-
The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system
-
Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, et al. (2000) The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 165: 5069-5076.
-
(2000)
J Immunol
, vol.165
, pp. 5069-5076
-
-
Papadakis, K.A.1
Prehn, J.2
Nelson, V.3
Cheng, L.4
Binder, S.W.5
-
14
-
-
0034899072
-
CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease
-
Papadakis KA, Prehn J, Moreno ST, Cheng L, Kouroumalis EA, et al. (2001) CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 21: 246-254.
-
(2001)
Gastroenterology
, vol.21
, pp. 246-254
-
-
Papadakis, K.A.1
Prehn, J.2
Moreno, S.T.3
Cheng, L.4
Kouroumalis, E.A.5
-
15
-
-
84875131659
-
Presence of CCR9 and its ligand CCL25/TECK in the colon: scientific rationale for the use of CCR9 small molecule antagonist CCX282-B in colonic disorders
-
Walters MJ, Berahovich R, Wang Y, Wei Z, Ungashe S, et al. (2008) Presence of CCR9 and its ligand CCL25/TECK in the colon: scientific rationale for the use of CCR9 small molecule antagonist CCX282-B in colonic disorders. Gut 57 (Suppl II): A39 (OP184).
-
(2008)
Gut
, vol.57
, Issue.SUPPL. II
-
-
Walters, M.J.1
Berahovich, R.2
Wang, Y.3
Wei, Z.4
Ungashe, S.5
-
16
-
-
27644441529
-
Natalizumab induction and maintenance therapy for Crohn's disease
-
Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, et al. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912-1925.
-
(2005)
N Engl J Med
, vol.353
, pp. 1912-1925
-
-
Sandborn, W.J.1
Colombel, J.F.2
Enns, R.3
Feagan, B.G.4
Hanauer, S.B.5
-
17
-
-
34247884424
-
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial
-
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, et al. (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132: 1672-1683.
-
(2007)
Gastroenterology
, vol.132
, pp. 1672-1683
-
-
Targan, S.R.1
Feagan, B.G.2
Fedorak, R.N.3
Lashner, B.A.4
Panaccione, R.5
-
18
-
-
34447523749
-
Certolizumab pegol for the treatment of Crohn's disease
-
Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, et al. (2007) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228-238.
-
(2007)
N Engl J Med
, vol.357
, pp. 228-238
-
-
Sandborn, W.J.1
Feagan, B.G.2
Stoinov, S.3
Honiball, P.J.4
Rutgeerts, P.5
-
19
-
-
32044451548
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
-
Hanauer SB, Sandborn WJ, Rutgeers P, Fedorak RN, Lukas M, et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323-333.
-
(2006)
Gastroenterology
, vol.130
, pp. 323-333
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Rutgeers, P.3
Fedorak, R.N.4
Lukas, M.5
-
20
-
-
70449100743
-
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
-
Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, et al. (2009) Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374; 1617-1625.
-
(2009)
Lancet
, vol.374
, pp. 1617-1625
-
-
Beaugerie, L.1
Brousse, N.2
Bouvier, A.M.3
Colombel, J.F.4
Lemann, M.5
|